Table 3.

Incidence and severity of non-neoplastic lesions at the site of application in F344/N rats and B6C3F1/N mice treated dermally for 2 years with pyrogallol.

Dose (mg/kg)	Hyperplasia	Hyperkerat osis	Inflammation	Fibrosis	Pigmentation	Sebaceous gland hyperplasia	Ulcer
Male F344/N rats
0	0	0	0	0	0	0	0
5	6* (1.0)	2 (1.0)	0	0	0	0	0
20	20** (1.0)	21** (1.0)	0	0	0	12** (1.0)	0
75	50** (1.2)	48** (1.6)	46** (1.3)	0	0	48** (1.1)	0
Female F344/N rats
0	0	0	0	0	0	0	0
5	9** (1.0)	6* (1.0)	3 (1.0)	0	0	0	0
20	11** (1.0)	22** (1.0)	6* (1.0)	0	0	5* (1.0)	0
75	49** (1.1)	49** (1.8)	49** (1.4)	0	0	41** (1.7)	0
Male B6C3F1/N mice
0	8 (1.3)	11 (1.5)	2 (1.5)	3 (2.0)	0	1 (2.0)	1 (2.0)
5	24** (1.2)	43** (1.3)	6 (1.7)	6 (1.7)	0	6 (1.3)	1 (3.0)
20	47** (1.6)	50** (1.9)	37** (1.2)	28** (1.4)	9** (1.0)	4 (1.3)	2 (2.5)
75	50** (2.5)	50** (2.6)	44** (2.4)	47** (2.5)	39** (1.5)	24** (1.5)	23** (3.0)
Female B6C3F1/N mice
0	20 (1.4)	24 (1.5)	12 (1.3)	5 (1.8)	0	1 (1.1)	2 (3.0)
5	31* (1.3)	38** (1.4)	14 (1.1)	6 (1.3)	0	2 (1.0)	0
20	49** (1.9)	49** (2.7)	42** (1.2)	31** (1.3)	35** (1.0)	6 (1.2)	3 (1.3)
75	49** (3.3)	49** (3.4)	48** (3.0)	49** (3.1)	40** (1.8)	34** (1.5)	33** (3.1)

N = 50. Average severity grades indicated in parenthesis: 1=minimal, 2=mild, 3=moderate, 4=marked.

Significant differences from vehicle control group:

^**p ≤ 0.01 by Fisher exact test.